JPWO2022232558A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022232558A5 JPWO2022232558A5 JP2023566870A JP2023566870A JPWO2022232558A5 JP WO2022232558 A5 JPWO2022232558 A5 JP WO2022232558A5 JP 2023566870 A JP2023566870 A JP 2023566870A JP 2023566870 A JP2023566870 A JP 2023566870A JP WO2022232558 A5 JPWO2022232558 A5 JP WO2022232558A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- sequence set
- siglec
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182271P | 2021-04-30 | 2021-04-30 | |
| US63/182,271 | 2021-04-30 | ||
| PCT/US2022/027006 WO2022232558A1 (en) | 2021-04-30 | 2022-04-29 | Anti-siglec compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515879A JP2024515879A (ja) | 2024-04-10 |
| JP2024515879A5 JP2024515879A5 (https=) | 2025-03-17 |
| JPWO2022232558A5 true JPWO2022232558A5 (https=) | 2025-03-17 |
Family
ID=83848703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566870A Pending JP2024515879A (ja) | 2021-04-30 | 2022-04-29 | 抗ｓｉｇｌｅｃ組成物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240218067A1 (https=) |
| EP (1) | EP4329806A4 (https=) |
| JP (1) | JP2024515879A (https=) |
| KR (1) | KR20240006519A (https=) |
| CN (1) | CN117355331A (https=) |
| AU (1) | AU2022267362A1 (https=) |
| CA (1) | CA3216324A1 (https=) |
| IL (1) | IL308137A (https=) |
| MX (1) | MX2023012759A (https=) |
| TW (1) | TW202305005A (https=) |
| WO (1) | WO2022232558A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117643575B (zh) * | 2023-11-03 | 2026-04-24 | 中山大学 | 一种纳米材料及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120171114A1 (en) * | 2008-04-11 | 2012-07-05 | Haeuw Jean-Francois | Anti-cd151 antibodies and their use in the treatment of cancer |
| US8163281B2 (en) * | 2009-03-04 | 2012-04-24 | The Regents Of The University Of Michigan | Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
| TW201612518A (en) * | 2014-01-17 | 2016-04-01 | Sanofi Sa | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody |
| CA3004972A1 (en) * | 2015-11-17 | 2017-05-26 | Innate Pharma | Siglec-10 antibodies |
| KR20210143868A (ko) * | 2019-03-26 | 2021-11-29 | 포티 세븐, 인코포레이티드 | 암 치료용 다중특이성 제제 |
-
2022
- 2022-04-29 TW TW111116333A patent/TW202305005A/zh unknown
- 2022-04-29 MX MX2023012759A patent/MX2023012759A/es unknown
- 2022-04-29 EP EP22796839.3A patent/EP4329806A4/en active Pending
- 2022-04-29 KR KR1020237036789A patent/KR20240006519A/ko active Pending
- 2022-04-29 CN CN202280031124.9A patent/CN117355331A/zh active Pending
- 2022-04-29 WO PCT/US2022/027006 patent/WO2022232558A1/en not_active Ceased
- 2022-04-29 JP JP2023566870A patent/JP2024515879A/ja active Pending
- 2022-04-29 AU AU2022267362A patent/AU2022267362A1/en active Pending
- 2022-04-29 US US18/558,112 patent/US20240218067A1/en active Pending
- 2022-04-29 CA CA3216324A patent/CA3216324A1/en active Pending
- 2022-04-29 IL IL308137A patent/IL308137A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma | |
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| BR112018012801B1 (pt) | Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica | |
| JP2020508317A5 (https=) | ||
| RU2679119C2 (ru) | Лечение неопластических заболеваний | |
| JP2020510704A5 (https=) | ||
| JP2018522851A5 (https=) | ||
| TW201922282A (zh) | Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2021511372A5 (https=) | ||
| TW202545570A (zh) | 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用 | |
| WO2025082449A1 (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| JPWO2022232558A5 (https=) | ||
| CN103417965B (zh) | 一种含有抗vegf抗体的药物组合物 | |
| CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| JPWO2020223702A5 (https=) | ||
| TW202214287A (zh) | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 | |
| WO2021180027A1 (zh) | 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法 | |
| Tempero et al. | Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma | |
| HK40124723A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| KR20260058844A (ko) | 전립선암 치료를 위한 조합 요법 | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| TW201922292A (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| HK40025415A (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer |